A number of drugs are effective for the treatment of bone tumors, but their systemic administration is inexorably associated with important counter-effects and lack of selectivity.
Targeting specific biochemical pathways inside bone cancer loci may theoretically furnish a tool to enhance the efficacy and safety of potentially valid anticancer agents.